Ovarian Cancer Response Scoring (OCRS): Validation of a system to quantify histopathological response to neoadjuvant chemotherapy in high-grade serous ovarian cancer

被引：0
|
作者：
Singh, N. [1 ]
Said, I. [1 ]
Faruqi, A. [1 ]
Gilks, B. [1 ]
Le, N. [1 ]
Boehm, S. [1 ]
机构：
[1] Barts Hlth NHS Trust, Dept Cellular Pathol, London, England
来源：
VIRCHOWS ARCHIV | 2014年 / 465卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
OFP-14-004
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [31] Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer
    Piedimonte, Sabrina
    Kim, Rachel
    Bernardini, Marcus Q.
    Atenafu, Eshetu G.
    Clark, Mitchell
    Lheureux, Stephanie
    May, Taymaa
    GYNECOLOGIC ONCOLOGY, 2022, 167 (03) : 417 - 422
  • [32] Tissue is the issue: Chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC)
    Knickerbocker, Abbey
    Kuchta, Kristine
    Donaldson, Carolyn
    Moore, Elena Diaz
    Lippitt, Melissa
    Rodriguez, Gustavo
    Watkin, William
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S241 - S242
  • [33] Tissue is the issue: chemotherapy response score (CRS) is most predictive of response to neoadjuvant chemotherapy in advanced, high grade serous ovarian cancer (HGSOC)
    Knickerbocker, Abbey
    Kuchta, Kristine
    Donaldson, Carolyn
    Moore, Elena Diaz
    Lippitt, Melissa
    Rodriguez, Gustavo
    Watkin, William
    Vogel, Tilley Jenkins
    GYNECOLOGIC ONCOLOGY, 2022, 165 : S10 - S11
  • [34] Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
    Lee, J-Y.
    Paik, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy
    Lee, Yong J.
    Kim, Dachan
    Shim, Jung E.
    Bae, Su-Jin
    Jung, Yu-Jin
    Kim, Sora
    Lee, Hanna
    Kim, So H.
    Jo, Su B.
    Lee, Jung-Yun
    Kim, Hyun-Soo
    Paik, Soonmyung
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (07) : 1851 - 1861
  • [36] New prognostic index for neoadjuvant chemotherapy outcome in patients with advanced high-grade serous ovarian cancer
    Huo, Chuying
    Wu, Bin
    Ye, Dongdong
    Xu, Miaochun
    Ma, Shaolin
    Cheng, Aoshuang
    Liu, Yunyun
    Huang, Chunxian
    Zhang, Yuhao
    Lin, Zhongqiu
    Li, Bowen
    Lu, Huaiwu
    BMC CANCER, 2024, 24 (01)
  • [37] Neoadjuvant treatment as a window to chemotherapy driven alterations to the genome and transcriptome of high-grade serous ovarian cancer
    Javellana, Melissa
    Eckert, Mark
    Stock, Elizabeth
    Chapel, David
    Lastra, Ricardo
    Lengyel, Ernst
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S210 - S210
  • [38] High-grade serous Ovarian Cancer: TP53 Mutations and Platinum Response
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (07)
  • [39] Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
    Stanske, Mandy
    Wienert, Stephan
    Castillo-Tong, Dan Cacsire
    Kreuzinger, Caroline
    Vergote, Ignace
    Lambrechts, Sandrijne
    Gabra, Hani
    Gourley, Charlie
    Ganapathi, Ram N.
    Kolaschinski, Ivonne
    Budczies, Jan
    Sehouli, Jalid
    Ruscito, Ilary
    Denkert, Carsten
    Kulbe, Hagen
    Schmitt, Wolfgang
    Johrens, Korinna
    Braicu, Ioana
    Darb-Esfahani, Silvia
    NEOPLASIA, 2018, 20 (03): : 280 - 288
  • [40] Phylogenetic and signature analyses predict treatment response in high-grade serous ovarian cancer
    Oikkonen, Jaana
    Li, Yilin
    Alkodsi, Amjad
    Carpen, Olli
    Huhtinen, Kaisa
    Hietanen, Sakari
    Grenman, Seija E.
    Lehtonen, Rainer
    Hautaniemi, Sampsa
    CANCER RESEARCH, 2018, 78 (13)
12345